Fibrate therapy and circulating adiponectin concentrations: Asystematic review and meta-analysis of randomized placebo-controlled trials

Atherosclerosis

Volumn 230, Issue 1, 2013, Pages 110-120

  Sahebkar, Amirhossein ^a,b   Watts, Gerald F ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adipokine; Cardiovascular disease; Dyslipidemia; Fibric acid; Lipid lowering drugs; Randomized controlled trial

Indexed keywords

ADIPONECTIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; EFFECT SIZE; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SMOKING; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ADIPOKINE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; FIBRIC ACID; LIPID-LOWERING DRUGS; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; DYSLIPIDEMIAS; FENOFIBRATE; GENE EXPRESSION REGULATION; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RESEARCH DESIGN; RISK; TRIGLYCERIDES;

EID: 84881642500     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.06.026     Document Type: Review

References (99)

1. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939-949.
2. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. JClin Endocrinol Metab 2004, 89:2548-2556.
3. Meier U., Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004, 50:1511-1525.
4. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. Anovel serum protein similar to C1q, produced exclusively in adipocytes. JBiol Chem 1995, 270:26746-26749.
5. Trujillo M.E., Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. JIntern Med 2005, 257:167-175.
6. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101:10308-10313.
7. Kumada M., Kihara S., Sumitsuji S., et al. Osaka CAD Study Group: Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
8. Zoccali C., Mallamaci F., Tripepi G. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. JAm Soc Nephrol 2002, 13:134-141.
9. Marso S.P., Mehta S.K., Frutkin A., House J.A., McCrary J.R., Kulkarni K.R. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in non-diabetic coronary arteries. Diabetes Care 2008, 31:989-994.
10. von Eynatten M., Humpert P.M., Bluemm A., et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008, 199:123-128.
11. Suwaidi J.A., Wright R.S., Grill J.P., et al. Obesity is associated with premature occurrence of acute myocardial infarction. Clin Cardiol 2001, 24:542-547.
12. Wolk R., Berger P., Lennon R.J., Brilakis E.S., Davison D.E., Somers V.K. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292-298.
13. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
14. Schulze MB., Shai I., Rimm EB., Li T., Rifai N., Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539.
15. Kazumi T., Kawaguchi A., Sakai K., Hirano T., Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002, 25:971-976.
16. Perelas A., Tsoulkani A., Perrea D. Effects of lipid-lowering drugs on adiponectin. Curr Vasc Pharmacol 2010, 8:836-848.
17. Wanders D., Plaisance E.P., Judd R.L. Lipid-lowering drugs and circulating adiponectin. Vitam Horm 2012, 90:341-374.
18. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009, 52:126-140.
19. Jun M., Foote C., Lv J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
20. Abourbih S., Filion K.B., Joseph L., et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009, 122(962):e1-e8.
21. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
22. ACCORD Study Group, Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362:1563-1574.
23. Chinetti-Gbaguidi G., Fruchart J.C., Staels B. Pleiotropic effects of fibrates. Curr Atheroscler Rep 2005, 7:396-401.
24. Tsimihodimos V., Miltiadous G., Daskalopoulou S.S., Mikhailidis D.P., Elisaf M.S. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005, 3:87-98.
25. Guerre-Millo M., Gervois P., Raspé E., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. JBiol Chem 2000, 275:16638-16642.
26. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1-13.
27. Mikhailidis D.P., Mathur S., Barradas M.A., Dandona P. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis. JCardiovasc Pharmacol 1990, 16. [platelet inhib/pd/ad/ae].
28. Tenenbaum A., Motro M., Fisman E.Z., et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202.
29. Tenenbaum A., Fisman E.Z., Boyko V., et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737-741.
30. Cariou B., Zaïr Y., Staels B., Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011, 34:2008-2014.
31. Perreault L., Bergman B.C., Hunerdosse D.M., Howard D.J., Eckel R.H. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. Metab Clin Exp 2011, 60:1107-1114.
32. Chan D.C., Watts G.F., Ooi E.M.M., Ji J., Johnson A.G., Barrett P.H.R. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1831-1837.
33. Koh K.K., Quon M.J., Shin K.C., et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis 2012, 220:537-544.
34. Koh K.K., Quon M.J., Lim S., et al. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis 2011, 214:144-147.
35. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
36. Rosenson R.S. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009, 17:504-509.
37. Belfort R., Berria R., Cornell J., Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. JClin Endocrinol Metab 2010, 95:829-836.
38. Wagner J.A., Larson P.J., Weiss S., et al. Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. JClin Pharmacol 2005, 45:504-513.
39. Ryan K.E., McCance D.R., Powell L., McMahon R., Trimble E.R. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007, 194:e123-e130.
40. Balasubramanyam A., Coraza I., Smith E.O., et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. JClin Endocrinol Metab 2011, 96:2236-2247.
41. Chan D.C., Wong A.T., Yamashita S., Watts G.F. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012, 221:484-489.
42. Hiuge A., Tenenbaum A., Maeda N., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007, 27:635-641.
43. Nakamura T., Kodama Y., Takano H., et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007, 193:449-451.
44. Powell L.A., Crowe P., Kankara C., et al. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation. Clin Sci (Lond) 2012, 123:135-146.
45. Anderlová K., Dolezalová R., Housová J., et al. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 2007, 56:579-586.
46. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
47. Cochrane handbook for systematic reviews of interventions version 5.0.2 2009, The Cochrane Collaboration. J.P.T. Higgins, S. Green (Eds.).
48. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 20:13.
49. Sahebkar A. Does PPARγ(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol, . doi:10.1089/dna.2012.1947.
50. Borenstein M., Hedges L., Higgins J., Rothstein H. Comprehensive meta-analysis version 2. Biostat Englewood NJ 2005.
51. Maeda N., Funahashi T., Shimomura I. Cardiovascular-metabolic impact of adiponectin and aquaporin. Endocr J 2013, 60:251-259.
52. Li F.Y.L., Lam K.S.L., Xu A. Therapeutic perspectives for adiponectin: an update. Curr Med Chem 2012, 19:5513-5523.
53. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51:2968-2974.
54. Maeda N., Takahashi M., Funahashi T., et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes 2001, 50:2094-2099.
55. Fujita K., Maeda N., Sonoda M., et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-α. Arterioscler Thromb Vasc Biol 2008, 28:863-870.
56. Mori Y., Oana F., Matsuzawa A., Akahane S., Tajima N. Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity. Endocrine 2004, 25:247-251.
57. Nakano S., Inada Y., Masuzaki H., et al. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase 370 Desiree Wanders, etal. type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2007, 292:E1213-E1222.
58. Choi K.C., Ryu O.H., Lee K.W., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336:747-753.
59. Naderali E.K., Fatani S., Telles M., Hunter L. The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue. Eur J Pharmacol 2008, 579:433-438.
60. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. JMed Chem 2000, 43:527-550.
61. Fernandez M., Gastaldelli A., Triplitt C., et al. Metabolic effects of muraglitazar in type 2 diabetic subjects. Diabetes Obes Metab 2011, 13:893-902.
62. Rydén M. Fibroblast growth factor 21: an overview from a clinical perspective. Cell Mol Life Sci 2009, 66:2067-2073.
63. Lin Z., Tian H., Lam K.S., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013, 17:779-789.
64. Dutchak P.A., Katafuchi T., Bookout A.L., et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
65. Li H., Gao Z., Zhang J., et al. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 2012, 61:797-806.
66. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. NEngl J Med 1987, 317:1237-1245.
67. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. NEngl J Med 1999, 341:410-418.
68. The Bezafibrate Infarction Prevention Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000, 102:21-27.
69. Bruckert E., Labreuche J., Deplanque D., Touboul P.J., Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. JCardiovasc Pharmacol 2011, 57:267-272.
70. Lee M., Saver J.L., Towfighi A., Chow J., Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011, 217:492-498.
71. Watts G.F., Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011, 97:350-356.
72. Cabré A., Lázaro I., Girona J., et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. JLipid Res 2008, 49:1746-1751.
73. Von Eynatten M., Hamann A., Twardella D., Nawroth P.P., Brenner H., Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patient with coronary heart disease. Clin Chem 2006, 52:853-859.
74. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
75. Zhu W., Cheng K.K., Vanhoutte P.M., Lam K.S., Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008, 114:361-374.
76. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009, 6:27-35.
77. Li R., Lau W.B., Ma X.L. Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol Sin 2010, 31:1258-1266.
78. Chinetti G., Zawadski C., Fruchart J.C., Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004, 314:151-158.
79. Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006, 536:182-191.
80. Metais C., Forcheron F., Abdallah P., et al. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin. Metabolism 2008, 57:946-953.
81. Haluzik M.M., Lacinova Z., Dolinkova M., et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 2006, 147:4517-4524.
82. Yamauchi T., Nio Y., Maki T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
83. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
84. Matsuura F., Oku H., Koseki M., et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007, 358:1091-1095.
85. Tsubakio-Yamamoto K., Matsuura F., Koseki M., et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008, 375:390-394.
86. Neumeier M., Sigruener A., Eggenhofer E., et al. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun 2007, 352:543-548.
87. Plant S., Shand B., Elder P., Scott R. Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diab Vasc Dis Res 2008, 5:102-108.
88. Xu S.Q., Mahadev K., Wu X., et al. Adiponectin protects against angiotensin II or tumor necrosis factor alpha-induced endothelial cell monolayer hyperpermeability: role of cAMP/PKA signaling. Arterioscler Thromb Vasc Biol 2008, 28:899-905.
89. Tian L., Luo N., Klein R.L., Chung B.H., Garvey W.T., Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2008, 202:152-161.
90. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
91. Hara K., Horikoshi M., Yamauchi T., et al. Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
92. Seino Y., Hirose H., Saito I., Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 2007, 56:1493-1499.
93. Eglit T., Lember M., Ringmets I., Rajasalu T. Gender differences in serum high-molecular-weight adiponectin levels in metabolic syndrome. Eur J Endocrinol 2013, 168:385-391.
94. Bottner A., Kratzsch J., Muller G., et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. JClin Endocrinol Metab 2004, 89:4053-4061.
95. Xu A., Chan K.W., Hoo R.L., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. JBiol Chem 2005, 280:18073-18080.
96. Boyne M.S., Bennett N.R., Cooper R.S., et al. Forrester TE. Sex-differences in adiponectin levels and body fat distribution: longitudinal observations in Afro-Jamaicans. Diabetes Res Clin Pract 2010, 90:e33-e36.
97. Iglesias M.J., Eiras S., Piñeiro R., et al. Gender differences in adiponectin and leptin expression in epicardial and subcutaneous adipose tissue. Findings in patients undergoing cardiac surgery. Rev Esp Cardiol 2006, 59:1252-1260.
98. Silva F.M., de Almeida J.C., Feoli A.M. Effect of diet on adiponectin levels in blood. Nutr Rev 2011, 69:599-612.
99. Saunders T.J., Palombella A., McGuire K.A., Janiszewski P.M., Després J.P., Ross R. Acute exercise increases adiponectin levels in abdominally obese men. JNutr Metab 2012, 2012:148729.